ES2610531T3 - Polipéptidos cosidos - Google Patents

Polipéptidos cosidos Download PDF

Info

Publication number
ES2610531T3
ES2610531T3 ES12159110.1T ES12159110T ES2610531T3 ES 2610531 T3 ES2610531 T3 ES 2610531T3 ES 12159110 T ES12159110 T ES 12159110T ES 2610531 T3 ES2610531 T3 ES 2610531T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
branched
unbranched
dical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12159110.1T
Other languages
English (en)
Spanish (es)
Inventor
Gregory L. Verdine
Young-Woo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Application granted granted Critical
Publication of ES2610531T3 publication Critical patent/ES2610531T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
ES12159110.1T 2007-03-28 2008-03-28 Polipéptidos cosidos Active ES2610531T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90856607P 2007-03-28 2007-03-28
US908566P 2007-03-28

Publications (1)

Publication Number Publication Date
ES2610531T3 true ES2610531T3 (es) 2017-04-28

Family

ID=39808865

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12159110.1T Active ES2610531T3 (es) 2007-03-28 2008-03-28 Polipéptidos cosidos
ES08744544T Active ES2430067T3 (es) 2007-03-28 2008-03-28 Polipéptidos cosidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08744544T Active ES2430067T3 (es) 2007-03-28 2008-03-28 Polipéptidos cosidos

Country Status (11)

Country Link
US (3) US8592377B2 (enExample)
EP (3) EP2142562B1 (enExample)
JP (5) JP5631201B2 (enExample)
KR (3) KR20160061439A (enExample)
CN (1) CN101730708B (enExample)
AU (1) AU2008232709C1 (enExample)
BR (1) BRPI0809366B8 (enExample)
CA (1) CA2682174C (enExample)
ES (2) ES2610531T3 (enExample)
IL (2) IL201227A (enExample)
WO (1) WO2008121767A2 (enExample)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
PL2332968T3 (pl) 2003-11-05 2017-08-31 Dana-Farber Cancer Institute, Inc. Stabilizowane alfa-helikalne peptydy i ich zastosowania
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2648687T3 (es) 2007-02-23 2018-01-05 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
ES2637687T3 (es) * 2007-05-02 2017-10-16 Dana-Farber Cancer Institute, Inc. Péptido BAD de dominio BH3 para usar en el tratamiento o retardo de la aparición de la diabetes
JP5653219B2 (ja) * 2007-12-31 2015-01-14 ニューヨーク ユニバーシティ 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御
CA2714251C (en) 2008-02-08 2017-08-15 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
EP2356139A4 (en) * 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
EP3492492A1 (en) 2008-09-22 2019-06-05 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
US20120178700A1 (en) * 2008-09-22 2012-07-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2342222B1 (en) * 2008-09-22 2018-03-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
ES2395028T3 (es) 2008-10-17 2014-05-30 Dana-Farber Cancer Institute, Inc. Péptidos del dominio citoplasmático de MUC-1 como inhibidores del cáncer
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
CN102223891A (zh) 2008-11-24 2011-10-19 爱勒让治疗公司 具有改善性质的拟肽大环化合物
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MX2011012625A (es) 2009-05-27 2012-04-20 Dana Faber Cancer Inst Inc Inhibicion de la inflamacion usando los antagonistas de mucina 1 (muc1).
CA2768299C (en) * 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
CN102655875A (zh) * 2009-10-14 2012-09-05 爱勒让治疗公司 改善的拟肽大环化合物
PT2493843E (pt) * 2009-10-28 2016-02-23 Xellia Pharmaceuticals Aps Ácido 2-amino-3-metil-hex-5-enoico e seu uso na produção de péptidos, tais como bacitracinas
US8685928B2 (en) 2010-02-12 2014-04-01 Dana-Farber Cancer Institute, Inc. Antagonists of MUC1
MX2013001131A (es) * 2010-07-28 2013-10-17 Amylin Pharmaceuticals Llc Compuestos agonistas del receptor del peptido similar al glucagon tipo 1 que tienen regiones estabilizadas.
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
US8957026B2 (en) * 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012061466A2 (en) * 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
AU2011325910B2 (en) * 2010-11-12 2016-03-24 Dana Farber Cancer Institute, Inc. Cancer therapies and diagnostics
AU2012242502B2 (en) 2011-04-15 2016-07-28 Dana-Farber Cancer Institute, Inc. Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
JP6342808B2 (ja) 2011-10-18 2018-06-13 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
CA2895930A1 (en) * 2011-12-21 2013-06-27 New York University Proteolytically resistant hydrogen bond surrogate helices
HK1208039A1 (en) 2011-12-29 2016-02-19 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
EP3769776A1 (en) 2012-02-15 2021-01-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
RS61957B1 (sr) 2012-09-26 2021-07-30 Harvard College Uvezani peptidi blokirani prolinom i njihove upotrebe
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
BR112015009470A2 (pt) * 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
SG11201508431VA (en) * 2013-03-13 2015-11-27 Harvard College Stapled and stitched polypeptides and uses thereof
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
BR112015031277A2 (pt) 2013-06-14 2017-09-19 Harvard College Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos
EP3052520A4 (en) * 2013-10-01 2017-12-06 President and Fellows of Harvard College Stabilized polypeptides and uses thereof
EP3116538A1 (en) 2014-03-10 2017-01-18 Fondation The Ark Respiratory syncytial virus (rsv) replication inhibitors
ES2776407T3 (es) 2014-03-20 2020-07-30 H Lee Moffitt Cancer Ct & Res Linfocitos infiltrantes de tumor para terapia celular adoptiva
WO2015153560A1 (en) 2014-03-31 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
US10189887B2 (en) 2014-04-17 2019-01-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides and uses thereof for reducing CD95-mediated cell motility
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
EP3197477A4 (en) 2014-09-24 2018-07-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG10201902594QA (en) * 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
EP3270945A4 (en) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selective mcl-1 binding peptides
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11155577B2 (en) 2015-06-22 2021-10-26 University Of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
CN107922461A (zh) * 2015-06-25 2018-04-17 南洋理工大学 广谱抗感染肽
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108026146A (zh) * 2015-07-02 2018-05-11 达纳-法伯癌症研究所股份有限公司 稳定的抗微生物肽
WO2017040329A2 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
CA2996685A1 (en) 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
US20190365913A1 (en) * 2016-02-04 2019-12-05 Tarveda Therapeutics, Inc. Stapled peptide conjugates and particles
WO2017151617A1 (en) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
CA3029622A1 (en) 2016-07-01 2018-01-04 Dana-Farber Cancer Institute, Inc. Compositions, assays, and methods for direct modulation of fatty acid metabolism
WO2018017485A1 (en) 2016-07-17 2018-01-25 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
AU2017315447B2 (en) 2016-08-26 2023-04-27 Dana-Farber Cancer Institute, Inc. Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
WO2018106937A1 (en) 2016-12-07 2018-06-14 The University Of Chicago Compositions and methods for inhibition of foxp3
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
WO2018174831A1 (en) * 2017-03-24 2018-09-27 Agency For Science, Technology And Research Stapled peptides
WO2018174826A1 (en) 2017-03-24 2018-09-27 Agency For Science, Technology And Research Building blocks for stapled peptides
CA3067047A1 (en) 2017-07-19 2019-01-24 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
BR112020004555A2 (pt) 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
CA3079758A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
CN120118207A (zh) 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解
AU2019218786B2 (en) 2018-02-07 2024-05-02 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
EP3765852A1 (en) 2018-03-14 2021-01-20 Dana Farber Cancer Institute, Inc. Stabilized peptides for biomarker detection
EP3802568A4 (en) 2018-06-08 2022-07-13 The Board of Regents of the University of Oklahoma PEPTIDE THERAPEUTICS USED TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EA202190531A1 (ru) 2018-08-20 2021-08-09 Фог Фармасьютикалз, Инк. Коллекции пептидов, пептидные агенты и способы их применения
US11286299B2 (en) 2018-09-17 2022-03-29 Massachusetts Institute Of Technology Peptides selective for Bcl-2 family proteins
CA3135115A1 (en) 2019-04-18 2020-10-22 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
US11345725B2 (en) 2019-09-16 2022-05-31 Research Foundation Of The City University Of New York Bis-thioether stapled peptides as inhibitors of PRC2 function
WO2021094608A1 (en) 2019-11-15 2021-05-20 Ospedale San Raffaele S.R.L. Chromogranin a-derived peptides and uses thereof
AU2020404876A1 (en) 2019-12-16 2022-07-21 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
US20230183309A1 (en) * 2019-12-20 2023-06-15 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3872170A1 (en) * 2020-02-25 2021-09-01 University of Georgia Research Foundation, Inc. Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (lrrk2)
AU2021230544A1 (en) 2020-03-04 2022-09-01 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized SARS-CoV-2 peptides and uses thereof
EP4139360A1 (en) 2020-04-22 2023-03-01 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
US20230192789A1 (en) 2020-04-27 2023-06-22 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
AU2021360898A1 (en) 2020-10-14 2023-03-23 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
EP4240395A1 (en) 2020-11-05 2023-09-13 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
CN112858395B (zh) * 2021-01-08 2022-12-27 中国工程物理研究院激光聚变研究中心 具有实时检测功能的放射性材料容器

Family Cites Families (594)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000259A (en) 1975-06-16 1976-12-28 American Home Products Corporation Cyclic dodecapeptide analogs of somatostatin and intermediates
US4438270A (en) 1977-07-11 1984-03-20 Merrell Toraude Et Compagnie α-Halomethyl derivatives of α-amino acids
US4191754A (en) 1979-02-28 1980-03-04 Merck & Co., Inc. Bicyclic somatostatin analogs
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
AU550730B2 (en) 1982-03-09 1986-04-10 Commonwealth Of Australia, The Automated metal detection
US4728726A (en) 1982-10-04 1988-03-01 The Salk Institute For Biological Studies GRF analogs IIIb
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US5416073A (en) 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5036045A (en) 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4730006A (en) 1986-01-27 1988-03-08 Merrell Dow Pharmaceuticals Inc. Derivatives of 2,6-diamino-3-haloheptanedioic acid
US4880778A (en) 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
HU206890B (en) 1986-10-13 1993-01-28 Sandoz Ag Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5112808A (en) 1987-05-11 1992-05-12 American Cyanamid Company Alkylated hormone-releasing peptides and method of treatig mammals therewith
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5877277A (en) 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5453418A (en) 1988-03-07 1995-09-26 Eli Lilly And Company Ractopamine and growth hormone combinations
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
WO1989009233A1 (en) 1988-03-24 1989-10-05 Terrapin Technologies, Inc. Molecular sticks for controlling protein conformation
US5094951A (en) 1988-06-21 1992-03-10 Chiron Corporation Production of glucose oxidase in recombinant systems
US5043322A (en) 1988-07-22 1991-08-27 The Salk Institute For Biological Studies Cyclic GRF analogs
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5384309A (en) 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5712418A (en) 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5169932A (en) 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
US5580957A (en) 1989-10-30 1996-12-03 The Salk Institute For Biological Studies GnRH analogs
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5245009A (en) 1990-03-23 1993-09-14 The Salk Institute For Biological Studies CRF antagonists
CA2047042A1 (en) 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
WO1992006998A1 (de) 1990-10-11 1992-04-30 Boehringer Ingelheim Kg Cyclopeptide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69118826T2 (de) 1990-11-27 1996-11-14 Fuji Photo Film Co Ltd Propenamidderivate, deren Polymere, Copolymere und deren Verwendung
US5124454A (en) 1990-11-30 1992-06-23 Minnesota Mining And Manufacturing Company Polycyclic diamines and method of preparation
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5744450A (en) 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
EP0525838A3 (en) 1991-04-09 1993-02-10 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5262519A (en) 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
GB9114949D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Novel compounds
DE69220861T2 (de) 1991-08-13 1997-11-20 Takeda Chemical Industries Ltd Zyklische Peptide und ihre Verwendung
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
IL103252A (en) 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0552417B1 (en) 1991-11-19 1999-07-07 Takeda Chemical Industries, Ltd. Cyclic peptides and use thereof
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
WO1996004289A1 (en) 1992-04-03 1996-02-15 California Institute Of Technology High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
WO1993024525A1 (en) 1992-05-26 1993-12-09 Rijksuniversiteit Leiden PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5371070A (en) 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
EP0684814B1 (en) 1993-02-22 1998-06-17 Alza Corporation Compositions for oral delivery of active agents
HUT72896A (en) 1993-03-29 1996-06-28 Du Pont Merck Pharma Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2161108A1 (en) 1993-04-23 1994-11-10 Herbert J. Evans Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
CZ292586B6 (cs) 1993-08-09 2003-10-15 Societe De Conseils De Recherches Et D´Application Somatostatinový nebo bombesidový derivát a jejich použití
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
JPH09505735A (ja) 1993-11-22 1997-06-10 オニックス ファーマシューティカルズ，インコーポレイティド ｐ５３−結合性ポリペプチド及びそれをコードするポリヌクレオチド
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
JPH09511496A (ja) 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド 細胞内メッセンジャー
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
JP3166482B2 (ja) 1994-06-07 2001-05-14 日産自動車株式会社 反射干渉作用を有する発色構造体
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US7553929B2 (en) 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5702908A (en) 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
EP1956374A1 (en) 1994-09-19 2008-08-13 Ricardo J. Moro Detection and treatment of cancer
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5681928A (en) 1994-12-16 1997-10-28 The Salk Institute For Biological Studies Betides and methods for screening peptides using same
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
EP0729972A1 (de) 1995-02-28 1996-09-04 F. Hoffmann-La Roche Ag Tetrahydronaphthalin-Peptidderivate
US5675001A (en) 1995-03-14 1997-10-07 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5700775A (en) 1995-03-24 1997-12-23 Gutniak; Mark K. Method and treatment composition for decreasing patient time in catabolic state after traumatic injury
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
EP0820296A4 (en) 1995-04-14 1999-06-30 Univ Tulane ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
AU711451B2 (en) 1995-05-04 1999-10-14 Scripps Research Institute, The Synthesis of proteins by native chemical ligation
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6020311A (en) 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
CA2222068C (en) 1995-05-26 2007-04-10 Theratechnologies Inc. Chimeric fatty body-pro-grf analogs with increased biological potency
US6458764B1 (en) 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
FR2738151B1 (fr) 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
US5750499A (en) 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
GB9521544D0 (en) 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
CZ195098A3 (cs) 1995-12-22 1998-10-14 Novo Nordisk A/S Sloučeniny uvolňující růstový hormon
US5807983A (en) 1995-12-28 1998-09-15 The Salk Institute For Biological Studies GNRH antagonist betides
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
EP0880357A4 (en) 1996-01-17 1999-05-12 California Inst Of Techn SYNTHESIS OF CONFORMATORICALLY RESTRICTED AMINO ACIDS, PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS BY CATALYTIC RINGCLOSE METATHESIS
AU4385696A (en) 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
US5849954A (en) 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
US5849691A (en) 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
IL126318A (en) 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JP3792777B2 (ja) 1996-05-10 2006-07-05 株式会社カネカ １−アルコキシカルボニル−３−フェニルプロピル誘導体の製造方法
WO1997044042A1 (en) 1996-05-22 1997-11-27 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US5817627A (en) 1996-06-14 1998-10-06 Theratechnologies Inc. Long-acting galenical formulation for GRF peptides
EP0812856B1 (en) 1996-06-14 1999-09-29 Takeda Chemical Industries, Ltd. Method for removing N-terminal methionine
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP0958305B1 (en) 1996-07-05 2008-06-04 Cancer Research Technology Limited Inhibitions of the interaction between p53 and mdm2
WO1998003473A1 (en) 1996-07-22 1998-01-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
AU4722197A (en) 1996-10-22 1998-05-15 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
DE69735241T2 (de) 1996-11-21 2006-11-02 Promega Corp., Madison Alkyl peptidamide für topische verwendung
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
CN1252808A (zh) 1997-02-20 2000-05-10 耶达研究及发展有限公司 抗病原合成肽及包含该肽类的组合物
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
WO1998046631A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
GB9708092D0 (en) 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
WO1998051707A1 (fr) 1997-05-15 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides a structures cycliques et a effet restaurateur d'activite de la proteine p53 sur les mutants de ladite proteine
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6127341A (en) 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
JP2001524301A (ja) 1997-09-17 2001-12-04 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ 新規治療用分子
WO1999016790A1 (en) 1997-09-26 1999-04-08 University Technologies International, Inc. Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6875594B2 (en) 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
US6177076B1 (en) 1997-12-09 2001-01-23 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
US6362276B1 (en) 1998-01-07 2002-03-26 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6030997A (en) 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
JP2002501907A (ja) 1998-01-29 2002-01-22 キナートン・リミテッド 吸収可能なマイクロ粒子の製造法
DE69916031T2 (de) 1998-01-29 2005-02-17 Poly-Med Inc. Asorbierbare mikropartikel
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
JP2002511483A (ja) 1998-04-15 2002-04-16 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド 樹脂結合環状ペプチドの製造方法
US6190699B1 (en) 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6194402B1 (en) 1998-09-02 2001-02-27 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
CA2360671A1 (en) 1999-01-29 2000-08-03 The Board Of Trustees Of The University Of Illinois P53 inhibitors and therapeutic use of the same
US6372490B1 (en) 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein
WO2000052210A2 (en) 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
PL350095A1 (en) 1999-03-29 2002-11-04 Procter & Gamble Ligands of melanocortinic receptors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
WO2000064283A1 (en) 1999-04-27 2000-11-02 International Health Products And Services Ltd. Supplement for restoring growth hormone levels
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
ATE318835T1 (de) 1999-05-17 2006-03-15 Conjuchem Inc Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6583299B1 (en) * 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
DE60030970T2 (de) 1999-05-24 2007-09-06 Introgen Therapeutics Inc., Austin Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
US6551996B1 (en) 1999-07-26 2003-04-22 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US6461634B1 (en) 1999-08-20 2002-10-08 Edward Marshall Food-based delivery of HGH-stimulating and other nutritional supplements
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20020016298A1 (en) 1999-09-01 2002-02-07 Hay Bruce A. Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
US6696418B1 (en) 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US20030181367A1 (en) 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
CA2392019A1 (en) 1999-11-22 2001-05-31 Zymogenetics, Inc. Method of forming a peptide-receptor complex with zsig33
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6579967B1 (en) 1999-12-14 2003-06-17 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
WO2001044807A1 (en) 1999-12-16 2001-06-21 Chugai Seiyaku Kabushiki Kaisha METHOD OF SCREENING REMEDY FOR CANCER WITH THE USE OF INTERACTION DOMAINS OF p53 AND MORTALIN
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
DE10009341A1 (de) 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US6495674B1 (en) 2000-02-25 2002-12-17 The Salk Institute For Biological Studies Evectins and their use
US20020002198A1 (en) 2000-04-17 2002-01-03 Parr Tyler B. Chemical synergy to elevate growth hormone release in vertebrates
US6495589B2 (en) 2000-04-28 2002-12-17 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
CA2380423A1 (en) 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
IL143690A0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
US7166712B2 (en) 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
IL144468A0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
US7049290B2 (en) 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
EP1305338A2 (en) 2000-08-02 2003-05-02 Theratechnologies Inc. Modified peptides with increased potency
US20040228866A1 (en) 2000-08-04 2004-11-18 Ludwig Institute For Cancer Research Suppressor genes
WO2002013833A2 (en) 2000-08-16 2002-02-21 Georgetown University Medical Center SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
AU7338801A (en) 2000-09-08 2002-03-22 Gryphon Sciences "pseudo"-native chemical ligation
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US20030074679A1 (en) 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
JP2004530422A (ja) 2000-12-19 2004-10-07 ザ ジョンズ ホプキンス ユニバーシティ 急速なアポトーシスを誘導するｊｆｙ１蛋白質
US20020091090A1 (en) 2000-12-28 2002-07-11 Cole Bridget M. Somatostatin antagonists and agonists
CU23157A1 (es) 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
US7268113B2 (en) 2001-02-02 2007-09-11 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
CA2439178C (en) 2001-02-23 2013-06-04 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
GB0104588D0 (en) 2001-02-24 2001-04-11 Univ Dundee Novel p-53 inducible protein
DE10109813A1 (de) 2001-03-01 2002-09-12 Thomas Stanislawski Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen
US20050054770A1 (en) 2001-03-09 2005-03-10 Spatola Arno F. Helicomimetics and stabilized lxxll peptidomimetics
US7019109B2 (en) 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs
KR20030088494A (ko) 2001-04-09 2003-11-19 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 소마토스타틴 작용제
US6368617B1 (en) 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
PT1392441E (pt) 2001-06-05 2008-09-30 Elan Pharma Int Ltd Sistema e método para trituração de materiais
WO2003004068A1 (en) 2001-07-06 2003-01-16 Auckland Uniservices Limited Hypertension treatment
JPWO2003014056A1 (ja) 2001-08-08 2004-11-25 鐘淵化学工業株式会社 光学活性２−置換カルボン酸の製造法
US20030157717A1 (en) 2001-09-07 2003-08-21 Baylor College Of Medicine Texas Medical Center Linear DNA fragments for gene expression
US20040106548A1 (en) 2001-09-07 2004-06-03 Schmidt Michelle A Conformationally constrained labeled peptides for imaging and therapy
US20020045192A1 (en) 2001-09-19 2002-04-18 St. Jude Children's Research Hospital Arf and HDM2 interaction domains and methods of use thereof
EP1312363A1 (en) 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US20030083241A1 (en) 2001-11-01 2003-05-01 Young Charles W. Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation
CN101157924A (zh) 2001-12-11 2008-04-09 人体基因组科学有限公司 嗜中性白细胞因子α
EP1321474A1 (en) 2001-12-18 2003-06-25 Universite De Geneve A method for inducing apoptosis
EP1455814B1 (en) 2001-12-18 2012-04-04 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin for use in the treatment of insulin resistance
US20050043231A1 (en) 2001-12-24 2005-02-24 Cutfield Wayne Stephen Therapy for growth hormone induced insulin resistance in juveniles with growth disorders
CA2471719A1 (en) 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
IL162604A0 (en) 2002-01-03 2005-11-20 Yissum Res Dev Co Conformationally constrained c-backbone cyclic peptides
US20040230380A1 (en) 2002-01-04 2004-11-18 Xencor Novel proteins with altered immunogenicity
TW200307749A (en) 2002-02-07 2003-12-16 Baylor College Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
CA2472956A1 (en) 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
US7432242B2 (en) 2002-02-15 2008-10-07 The Regents Of The University Of Michigan Inhibitors of RGS proteins
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
JP2005520562A (ja) 2002-03-26 2005-07-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 成長ホルモン分泌促進受容体（ｇｈｓ）に関連する疾患の診断および治療
US7498134B2 (en) 2002-03-30 2009-03-03 The Trustees Of Columbia University In The City Of New York HAUSP-Mdm2 interaction and uses thereof
CN100419426C (zh) 2002-04-22 2008-09-17 佛罗里达州立大学 功能化纳米微粒及其使用方法
WO2003095625A2 (en) 2002-05-13 2003-11-20 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
JP4638225B2 (ja) 2002-05-30 2011-02-23 ザ スクリプス リサーチ インスティテュート 銅を触媒とするアジドとアセチレンのライゲーション
AU2003247435A1 (en) 2002-05-30 2003-12-19 European Molecular Biology Laboratory Combinatorial chemical library ii
US7208154B2 (en) 2002-06-03 2007-04-24 Regents Of The University Of Michigan Methods and compositions for the treatment of MHC-associated conditions
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
AU2003253883A1 (en) 2002-07-15 2004-02-02 The Johns Hopkins University Neuronal and optic nerve gene expression patterns
AU2003259172A1 (en) 2002-07-24 2004-02-09 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
EP1541692A1 (en) 2002-09-06 2005-06-15 Kaneka Corporation PROCESS FOR PRODUCING L-a-METHYLCYSTEINE DERIVATIVE
AU2003267124A1 (en) 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US20060128615A1 (en) 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
WO2004026896A2 (en) 2002-09-23 2004-04-01 Medivir Ab Hcv ns-3 serine protease inhibitors
EP1947113B1 (en) 2002-10-07 2011-12-14 Ludwig Institute for Cancer Research Ltd P53 binding polypeptide
WO2004033645A2 (en) 2002-10-07 2004-04-22 Zymogenetics, Inc. Methods of regulating body weight
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
DE10393514T5 (de) 2002-10-24 2005-09-29 Dow Global Technologies, Inc., Midland Stabilisierung von Produktmischungen aus der Olefinmetathese
US20040152708A1 (en) 2002-11-07 2004-08-05 Yong Li Trans-9,10-dehydroepothilone C and D, analogs thereof and methods of making the same
CA2503117C (en) * 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
CA2511144A1 (en) 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20040204358A1 (en) 2003-01-28 2004-10-14 Advisys, Inc. Reducing culling in herd animals growth hormone releasing hormone (GHRH)
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1609802A4 (en) 2003-02-26 2006-06-21 Japan Science & Tech Agency TRANSCRIPTIONAL FACTOR INDUCING APOPTOSIS IN CANCER CELLS
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
WO2004084943A1 (en) 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US7632920B2 (en) 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
KR101161823B1 (ko) 2003-05-01 2012-07-03 코넬 리서치 화운데이션,인크. 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체
CA2525574C (en) 2003-05-15 2015-06-30 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
AU2003902743A0 (en) 2003-06-02 2003-06-19 Promics Pty Limited Process for the preparation of cyclic peptides
CA2528465A1 (en) 2003-06-09 2005-01-20 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
US20090198050A1 (en) 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
JP4928261B2 (ja) 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
WO2005000876A2 (en) 2003-06-27 2005-01-06 Proteologics, Inc. Ring finger family proteins and uses related thereto
WO2005007675A2 (en) 2003-07-09 2005-01-27 The Scripps Research Institute TRIAZOLE ϵ-AMINO ACIDS
US20070185031A1 (en) 2003-07-14 2007-08-09 Northwestern University Reducing polyglutamine-based aggregation
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
EP1668116A4 (en) 2003-08-20 2007-08-15 Northern Sydney And Central Co METHOD FOR IMPROVING EMBRYOVIABILITY
WO2005018682A2 (en) 2003-08-20 2005-03-03 The Regents Of The University Of California Somatostatin analogs with inhibitory activity to growth hormone release
WO2005027913A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
ATE396973T1 (de) 2003-10-03 2008-06-15 Merck & Co Inc Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
WO2005039546A2 (en) 2003-10-03 2005-05-06 Veijlen N.V. Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
GB0323728D0 (en) 2003-10-10 2003-11-12 Royal College Of Surgeons Ie Peptidomimetics and uses thereof
WO2005040202A2 (en) 2003-10-16 2005-05-06 Aplagen Gmbh Stabilized alpha-helical peptides
WO2005044840A2 (en) 2003-10-17 2005-05-19 The Cbr Institute For Biomedical Research, Inc. Modulation of anergy and methods for isolating anergy-modulating compounds
CA2542433A1 (en) 2003-10-20 2005-04-28 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
US7273927B2 (en) 2003-11-03 2007-09-25 University Of Massachusetts Mdm2 splice variants
PL2332968T3 (pl) 2003-11-05 2017-08-31 Dana-Farber Cancer Institute, Inc. Stabilizowane alfa-helikalne peptydy i ich zastosowania
US20050147581A1 (en) 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
US7772367B2 (en) 2004-01-30 2010-08-10 The Trustees Of Columbia University In The City Of New York C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
US20070161551A1 (en) 2004-02-10 2007-07-12 De Luca Giampiero Methods and compositions for the treatment of lipodystrophy
GB0404731D0 (en) 2004-03-03 2004-04-07 Indp Administrative Inst Nims Method and products for the selective degradation of proteins
US20050203009A1 (en) 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
CA2565324A1 (en) 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
JP2007532495A (ja) 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
US7034050B2 (en) 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
US7407929B2 (en) 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
ATE414693T1 (de) 2004-05-18 2008-12-15 Hoffmann La Roche Neuartige cis-imidazoline
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
US7501397B2 (en) 2004-06-04 2009-03-10 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity
CN100335467C (zh) 2004-06-04 2007-09-05 中国科学院上海有机化学研究所 一锅法区域选择性合成5－碘代－1，4－二取代－1，2，3－三氮唑化合物
EP1602663A1 (en) 2004-06-04 2005-12-07 Chiralix B.V. Triazole-linked glycoamino acids and glycopeptides
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
CN101076349B (zh) 2004-08-12 2012-08-22 蓝宝石治疗公司 生长激素促分泌素用于制备刺激胃肠系统动力的药物的用途
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
AU2005277389A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US7402652B2 (en) 2004-09-14 2008-07-22 Miller Landon C G Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7074775B2 (en) 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
US7157421B2 (en) 2004-12-27 2007-01-02 Miller Landon C G Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders
US9598470B2 (en) 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
KR101228229B1 (ko) 2004-10-20 2013-01-31 쎄러테크놀로지스 인코포레이티드 성장 호르몬 분비 촉진물질 및 그의 용도
EP1814860B1 (en) 2004-10-29 2009-06-03 Schering Corporation Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006069001A2 (en) 2004-12-20 2006-06-29 Baylor College Of Medicine Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands
GB0428187D0 (en) 2004-12-23 2005-01-26 Univ Liverpool Cancer treatment
CA2595902C (en) 2005-01-24 2017-08-22 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
FR2881430B1 (fr) 2005-02-01 2010-10-22 Servier Lab Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
JP2008535486A (ja) 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
WO2006122931A1 (en) 2005-05-20 2006-11-23 Biovitrum Ab (Publ) Beta-carboline derivatives and theri use as ghsr modulators
EP1891090A2 (en) 2005-06-13 2008-02-27 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US20090275648A1 (en) 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US20070020620A1 (en) 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
WO2007009191A1 (en) 2005-07-21 2007-01-25 Newsouth Innovations Pty Limited Method for treating cancer
ES2410132T3 (es) 2005-07-22 2013-07-01 Ipsen Pharma Secretagogos de la hormona del crecimiento.
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
EP1928489B1 (en) 2005-09-28 2014-03-26 Ipsen Pharma Analogs of ghrelin
US20070161544A1 (en) 2006-01-06 2007-07-12 Peter Wipf Selective targeting agents for mitcochondria
EP1986673A2 (en) 2006-02-13 2008-11-05 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health and Human Services Methods and compositions related to ghs-r antagonists
US7538190B2 (en) 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
US7745573B2 (en) 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23592A1 (es) 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
CN101443358B (zh) 2006-03-13 2016-05-11 利亚特·明茨 生长素释放肽剪接变体在治疗恶病质和/或压食和/或厌食-恶病质和/或营养不良和/或脂肪营养障碍和/或肌肉消耗和/或刺激食欲中的用途
US20100179168A1 (en) 2006-04-13 2010-07-15 Emma Louise Blaney Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
WO2007127457A2 (en) 2006-04-28 2007-11-08 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
BRPI0713119A2 (pt) 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
US20080004286A1 (en) 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
JP2009542813A (ja) 2006-07-11 2009-12-03 ハルクネスス プハルマセウティカルス，インコーポレイテッド 飽食因子を使用して肥満を治療する方法
US20100322945A1 (en) 2006-07-26 2010-12-23 Peter Timmerman Immunogenic compounds and protein mimics
US8614192B2 (en) 2006-07-28 2013-12-24 Leiden University Medical Center Method for treating ocular cancer
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
JP5506386B2 (ja) 2006-09-04 2014-05-28 ユニバーシティー・コート・オブ・ザ・ユニバーシティー・オブ・ダンディー Ｐ５３活性化化合物
WO2008033557A2 (en) 2006-09-15 2008-03-20 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclic peptidomimetics as integrin markers
US7897394B2 (en) 2006-09-21 2011-03-01 Intrexon Corporation Endoplasmic reticulum localization signals
ES2342854T3 (es) 2006-09-21 2010-07-15 F. Hoffmann-La Roche Ag Derivados de oxindol como agentes anticancerosos.
WO2008039415A2 (en) 2006-09-27 2008-04-03 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the n-terminal
BRPI0717327A2 (pt) 2006-09-28 2014-09-30 Arete Therapeutics Inc Inibidores da epóxido hidrolase solúvel
WO2008045238A2 (en) 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
KR100860060B1 (ko) 2006-10-12 2008-09-24 한국과학기술연구원 ＨＩＦ-１α Ｃ-말단 펩타이드와 ＣＢＰ 또는 ｐ３００단백질과의 결합을 정량분석하는 방법 및 상기 방법을이용한 단백질 복합체 형성을 저해하는 억제제의 스크리닝방법
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
ES2526292T3 (es) 2006-10-16 2015-01-09 The Salk Institute For Biological Studies Antagonistas de la somatostatina selectivos para receptor (SSTR2)
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
US7932397B2 (en) 2006-11-22 2011-04-26 Massachusetts Institute Of Technology Olefin metathesis catalysts and related methods
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
WO2008074895A1 (en) 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular ccr5 peptide conjugates and uses thereof
WO2008092281A1 (en) 2007-01-29 2008-08-07 Polyphor Ltd. Template-fixed peptidomimetics
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
CN101244053B (zh) 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
ES2648687T3 (es) 2007-02-23 2018-01-05 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
WO2008112941A1 (en) 2007-03-13 2008-09-18 Board Of Regents The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2637687T3 (es) 2007-05-02 2017-10-16 Dana-Farber Cancer Institute, Inc. Péptido BAD de dominio BH3 para usar en el tratamiento o retardo de la aparición de la diabetes
WO2008150479A2 (en) 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
WO2009009727A2 (en) 2007-07-12 2009-01-15 Akela Pharma Srl Ghrh analogs and therapeutic uses thereof
RU2007133287A (ru) 2007-09-05 2009-03-10 Ионов Иль Давидович (RU) Противопсориатическое средство и способ его применения (варианты)
JP2010539063A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｇｒｆ−１（１−２９）および副腎皮質刺激ホルモン放出因子の、治療剤としての使用
WO2009046850A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Cgrp as a therapeutic agent
WO2009033768A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2197431A4 (en) 2007-09-17 2013-03-27 Olas Pharmaceuticals Inc MODULATION OF GROWTH HORMONE, DHEA AND CORTISOL USING POSITIVE MODULATORS OF AMPA-TYPE GLUTAMATE RECEPTORS
JP5438008B2 (ja) 2007-09-21 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
US8921323B2 (en) 2007-09-26 2014-12-30 Dana Farber Cancer Institute, Inc. Methods and compositions for modulating BCL-2 family polypeptides
DK2225271T3 (da) 2007-12-03 2013-10-07 Italfarmaco Spa Nye ikke-selektive somatostatin-analoger
JP5653219B2 (ja) 2007-12-31 2015-01-14 ニューヨーク ユニバーシティ 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
WO2009094201A2 (en) 2008-01-25 2009-07-30 Trustees Of Boston College Catalysts for metathesis reactons including enantioselective olefin metathesis, and related methods
EP2245464B1 (en) 2008-01-25 2016-12-14 MultiVir Inc. P53 biomarkers
CA2714251C (en) 2008-02-08 2017-08-15 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
WO2009126292A2 (en) 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
EP2283033A1 (en) 2008-05-06 2011-02-16 New York Blood Center Antiviral cell penetrating peptides
EP2285970A4 (en) 2008-06-03 2011-10-12 Aileron Therapeutics Inc COMPOSITIONS AND METHODS FOR REINFORCING THE CELL TRANSPORT OF BIOMOLECULES
WO2009149339A2 (en) 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
US20110158973A1 (en) 2008-06-12 2011-06-30 Syntaxin Limited Suppression of cancers
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
EP2310028B1 (en) 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
CA2728735A1 (en) 2008-06-25 2009-12-30 Braasch Biotech Llc Compositions and methods for enhanced somatostatin immunogenicity
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
GB0813873D0 (en) 2008-07-30 2008-09-03 Univ Dundee Compounds
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2334317B1 (en) 2008-09-16 2017-06-14 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
WO2010033879A2 (en) 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
CA2737914A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102197048A (zh) 2008-09-22 2011-09-21 爱勒让治疗公司 拟肽大环化合物
JP2012503024A (ja) 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
EP3492492A1 (en) 2008-09-22 2019-06-05 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
US20120178700A1 (en) 2008-09-22 2012-07-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2342222B1 (en) 2008-09-22 2018-03-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6049260B2 (ja) 2008-10-10 2016-12-21 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド プロアポトーシスｂａｘ及びｂｃｌ−２ポリペプチドの化学モジュレータ
JP2010120881A (ja) 2008-11-19 2010-06-03 Keio Gijuku ヒト癌タンパク質ＭＤＭ２とヒト癌抑制タンパク質ｐ５３との相互作用阻害ペプチド及びその使用
KR101298168B1 (ko) 2008-11-21 2013-08-20 충남대학교산학협력단 스네일―ｐ５３ 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
CN102223891A (zh) 2008-11-24 2011-10-19 爱勒让治疗公司 具有改善性质的拟肽大环化合物
WO2010065572A1 (en) 2008-12-04 2010-06-10 The Salk Institute For Biological Studies Sstr1-selective analogs
WO2010068684A2 (en) 2008-12-09 2010-06-17 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
US20100152114A1 (en) 2008-12-12 2010-06-17 Univ Of Miami And Usa By Dept Of Veterans Affairs Antioxidant activity of GH-RH Antagonists
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010083501A2 (en) 2009-01-16 2010-07-22 University Of South Florida Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20100239589A1 (en) 2009-02-23 2010-09-23 Salk Institute For Biological Studies Methods and Compositions for Ameliorating Diabetes and Symptoms Thereof
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
WO2010121352A1 (en) 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
EP2422201B1 (en) 2009-04-22 2015-04-22 The Walter and Eliza Hall Institute of Medical Research Structure of the c-terminal region of the insulin receptor alpha -chain and of the insulin-like growth factor receptor alpha -chain
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
US8883721B2 (en) 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
JP2010286127A (ja) 2009-06-09 2010-12-24 Daikin Ind Ltd 吸着熱交換器
WO2011005219A1 (en) 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US20120149661A1 (en) 2009-08-26 2012-06-14 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
CA2775925A1 (en) 2009-09-30 2011-04-07 Tranzyme Pharma, Inc. Salts, solvates and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same
CN102655875A (zh) 2009-10-14 2012-09-05 爱勒让治疗公司 改善的拟肽大环化合物
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
AU2010313282A1 (en) 2009-10-30 2012-05-24 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US20120283269A1 (en) 2009-11-04 2012-11-08 Health Research Inc. Method and Compositions for Suppression of Aging
KR20120099462A (ko) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8658170B2 (en) 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
KR101220516B1 (ko) 2010-01-21 2013-01-10 연세대학교 산학협력단 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도
EP2534140B1 (en) 2010-02-08 2018-04-11 Trustees of Boston College Efficient methods for z- or cis-selective cross-metathesis
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
CA2800519A1 (en) 2010-04-09 2011-10-13 The Regents Of The University Of Michigan Biomarkers for mdm2 inhibitors for use in treating disease
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
CA2805406A1 (en) 2010-06-16 2011-12-22 Mcgill University Growth hormone secretatogue receptor antagonists and uses thereof
WO2011163423A2 (en) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
US20110313167A1 (en) 2010-06-22 2011-12-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Substituted Heterocycles as Therapeutic agents for treating cancer
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
CA2796879A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
WO2012016186A1 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
AU2011299551A1 (en) 2010-09-08 2013-03-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P53-Mdm2 antagonists
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
EP2616095A4 (en) 2010-09-16 2014-03-19 Univ Miami WOUND HEALING ACCELERATION BY A GROWTH HORMONE RELEASING HORMON AND HIS AGONISTS
CN102399283B (zh) 2010-09-17 2013-05-29 中国农业大学 水貂生长激素释放激素cDNA及其应用
CN102399284B (zh) 2010-09-17 2013-05-29 中国农业大学 狐狸生长激素释放激素cDNA及其应用
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012047587A2 (en) 2010-09-27 2012-04-12 Serrata, Llc Mdm2 inhibitors for treatment of ocular conditions
ES2685175T3 (es) 2010-09-30 2018-10-05 St. Jude Children's Research Hospital Imidazoles sustituidos con arilo
EP2627662B1 (en) 2010-10-13 2015-09-16 Bristol-Myers Squibb Company Methods for preparing macrocycles and macrocycle stabilized peptides
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
US8680132B2 (en) 2010-11-12 2014-03-25 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
AU2011325910B2 (en) 2010-11-12 2016-03-24 Dana Farber Cancer Institute, Inc. Cancer therapies and diagnostics
WO2012076513A1 (en) 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
WO2012083181A1 (en) 2010-12-16 2012-06-21 Indiana University Research And Technology Corporation Alpha helix mimetics and methods for using
JP2014507384A (ja) 2010-12-16 2014-03-27 ロシュ グリクアート アーゲー Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法
AR084308A1 (es) 2010-12-17 2013-05-08 Syngenta Participations Ag Compuestos insecticidas derivados de triazol
EP2474624B1 (en) 2011-01-05 2016-08-17 Daniela Kandioler Response prediction in cancer treatment (p53 adapted cancer therapy)
EP2474625B1 (en) 2011-01-05 2016-11-02 Daniela Kandioler Method for determining the p53 status of a tumour
US20130302909A1 (en) 2011-01-14 2013-11-14 Theratechnologies Inc. Assessment of igf-1 levels in hiv-infected subjects and uses thereof
JP5950587B2 (ja) 2011-02-28 2016-07-13 キヤノン株式会社 多孔質ガラスの製造方法および光学部材の製造方法
CA2828889A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
US9376467B2 (en) 2011-03-09 2016-06-28 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
PT2684880T (pt) 2011-03-10 2018-04-27 Daiichi Sankyo Co Ltd Derivado de dispiropirrolidina
US20140213502A1 (en) 2011-04-29 2014-07-31 United States Department of Health and Human Services Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
EP2721061A4 (en) 2011-06-17 2014-11-05 Harvard College VARIANT STABILIZED MAML-PEPTIDES AND USES THEREOF
GB201110390D0 (en) 2011-06-20 2011-08-03 Medical Res Council Compounds for use in stabilising p53 mutants
US20120328692A1 (en) 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
CN103889437A (zh) 2011-08-31 2014-06-25 纽约大学 硫醚、醚和烷基胺连接的氢键替代物肽模拟物
EP3444262A3 (en) 2011-09-09 2019-04-10 Agency For Science, Technology And Research P53 activating peptides
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2013059530A2 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6342808B2 (ja) 2011-10-18 2018-06-13 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
WO2013062923A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2761253A1 (en) 2011-12-07 2013-06-07 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013116829A1 (en) 2012-02-03 2013-08-08 The Trustees Of Princeton University Novel engineered potent cytotoxic stapled bh3 peptides
EP3769776A1 (en) 2012-02-15 2021-01-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
US9890429B2 (en) 2012-02-29 2018-02-13 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
US9880171B2 (en) 2012-03-02 2018-01-30 Ludwig Institute For Cancer Research Ltd. iASPP phosphorylation and metastatic potential
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US9309284B2 (en) 2012-05-02 2016-04-12 Kansas State University Reasearch Foundation Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses
PL2880447T3 (pl) 2012-07-31 2019-10-31 Novartis Ag Markery związane z wrażliwością na inhibitory ludzkiego białka „double minute " 2 (mdm2)
EP2901154B1 (en) 2012-09-25 2018-11-21 The Walter and Eliza Hall Institute of Medical Research Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain
RS61957B1 (sr) 2012-09-26 2021-07-30 Harvard College Uvezani peptidi blokirani prolinom i njihove upotrebe
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
JP6266659B2 (ja) 2013-02-28 2018-01-24 アムジエン・インコーポレーテツド 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
SG11201508431VA (en) 2013-03-13 2015-11-27 Harvard College Stapled and stitched polypeptides and uses thereof
WO2014144121A2 (en) 2013-03-15 2014-09-18 Life Technologies Corporation Classification and actionability indices for lung cancer
US9198910B2 (en) 2013-04-04 2015-12-01 The Translational Genomics Research Institute Methods for the treatment of cancer
ES2782003T3 (es) 2013-04-16 2020-09-09 Memorial Sloan Kettering Cancer Center Compañero de diagnóstico para inhibidores de CDK4
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
BR112015031277A2 (pt) 2013-06-14 2017-09-19 Harvard College Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos
CN105378112B (zh) 2013-07-03 2020-10-13 豪夫迈·罗氏有限公司 用于将用MDM2拮抗剂进行患者癌症治疗个人化的基于mRNA的基因表达
US9268662B2 (en) 2013-08-01 2016-02-23 Oracle International Corporation Method and system for a high availability framework
WO2015017803A1 (en) 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
EP3052520A4 (en) 2013-10-01 2017-12-06 President and Fellows of Harvard College Stabilized polypeptides and uses thereof
US20160115556A1 (en) 2013-10-19 2016-04-28 Trovagene, Inc. Detecting mutations in disease over time
SMT202200241T1 (it) 2013-11-11 2022-09-14 Amgen Inc Politerapia che include un inibitore di mdm2 e uno o più agenti farmaceuticamente attivi aggiuntivi per il trattamento di cancri
CN105792847B (zh) 2013-12-05 2019-11-08 豪夫迈·罗氏有限公司 急性骨髓性白血病(aml)的新型组合治疗
MX2016008363A (es) 2013-12-23 2016-09-08 Novartis Ag Combinaciones farmaceuticas.
RU2016129953A (ru) 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
US20160333419A1 (en) 2014-01-14 2016-11-17 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
US20170037086A1 (en) 2014-04-09 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
WO2015179799A1 (en) 2014-05-22 2015-11-26 The General Hospital Corporation DD1alpha RECEPTOR AND USES THEREOF IN IMMUNE DISORDERS
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
AU2015314756A1 (en) 2014-09-13 2017-03-16 Novartis Ag Combination therapies of alk inhibitors
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
EP3197477A4 (en) 2014-09-24 2018-07-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016056673A1 (en) 2014-10-09 2016-04-14 Daiichi Sankyo Company, Limited Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors
WO2016055497A1 (en) 2014-10-10 2016-04-14 F. Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
KR20170095893A (ko) 2014-12-24 2017-08-23 제넨테크, 인크. 방광암에 대한 치료, 진단, 및 예후 방법
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108026146A (zh) 2015-07-02 2018-05-11 达纳-法伯癌症研究所股份有限公司 稳定的抗微生物肽
WO2017023933A2 (en) 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2996685A1 (en) 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
WO2017165299A2 (en) 2016-03-21 2017-09-28 Aileron Therapeutics, Inc. Companion diagnostic tool for peptidomimetic macrocycles
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
US20170360881A1 (en) 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Also Published As

Publication number Publication date
US20170066799A1 (en) 2017-03-09
JP6363122B2 (ja) 2018-07-25
IL201227A0 (en) 2010-05-31
AU2008232709C1 (en) 2015-01-15
JP2020007344A (ja) 2020-01-16
KR101623985B1 (ko) 2016-05-25
CA2682174C (en) 2021-04-06
AU2008232709A1 (en) 2008-10-09
US9556227B2 (en) 2017-01-31
CA2682174A1 (en) 2008-10-09
HK1140215A1 (en) 2010-10-08
EP2508531B1 (en) 2016-10-19
JP2010522769A (ja) 2010-07-08
BRPI0809366B1 (pt) 2021-02-23
BRPI0809366A8 (pt) 2019-01-29
JP2016094476A (ja) 2016-05-26
ES2430067T3 (es) 2013-11-18
EP2142562A2 (en) 2010-01-13
US10301351B2 (en) 2019-05-28
EP3159352B1 (en) 2023-08-02
CN101730708A (zh) 2010-06-09
IL221062B (en) 2018-06-28
US20100184645A1 (en) 2010-07-22
JP2018044018A (ja) 2018-03-22
JP2014193932A (ja) 2014-10-09
US8592377B2 (en) 2013-11-26
KR20160061439A (ko) 2016-05-31
EP2142562B1 (en) 2013-07-03
KR20090126308A (ko) 2009-12-08
KR20140117695A (ko) 2014-10-07
WO2008121767A3 (en) 2009-01-08
KR101525754B1 (ko) 2015-06-09
AU2008232709B2 (en) 2014-05-29
BRPI0809366A2 (pt) 2014-09-16
EP2508531A1 (en) 2012-10-10
IL201227A (en) 2017-11-30
CN101730708B (zh) 2013-09-18
EP3159352A1 (en) 2017-04-26
BRPI0809366B8 (pt) 2021-05-25
JP5631201B2 (ja) 2014-11-26
US20140011979A1 (en) 2014-01-09
WO2008121767A2 (en) 2008-10-09
IL221062A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
ES2610531T3 (es) Polipéptidos cosidos
US12258423B2 (en) Stapled and stitched polypeptides and uses thereof
ES2874525T3 (es) Péptidos grapados bloqueados con prolina y usos de los mismos
AU2017202063A1 (en) Stitched polypeptides
HK40047860A (en) Stapled and stitched polypeptides and uses thereof
HK1262748A1 (en) Stapled and stitched polypeptides and uses thereof
HK1140215B (en) Stitched polypeptides
HK1213269B (en) Proline-locked stapled peptides and uses thereof